Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Jul;74(7):863–866. doi: 10.1136/jnnp.74.7.863

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

S Akhondzadeh 1, M Noroozian 1, M Mohammadi 1, S Ohadinia 1, A Jamshidi 1, M Khani 1
PMCID: PMC1738567  PMID: 12810768

Abstract

Objective: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease.

Design: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran.

Methods: Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of ≥ 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and ≤ 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded.

Results: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03).

Conclusions: Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.

Full Text

The Full Text of this article is available as a PDF (153.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballard Clive G., O'Brien John T., Reichelt Katharina, Perry Elaine K. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002 Jul;63(7):553–558. doi: 10.4088/jcp.v63n0703. [DOI] [PubMed] [Google Scholar]
  2. Bullock Roger. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry. 2002 Feb;180:135–139. doi: 10.1192/bjp.180.2.135. [DOI] [PubMed] [Google Scholar]
  3. Evans D. A., Funkenstein H. H., Albert M. S., Scherr P. A., Cook N. R., Chown M. J., Hebert L. E., Hennekens C. H., Taylor J. O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989 Nov 10;262(18):2551–2556. [PubMed] [Google Scholar]
  4. Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137–147. doi: 10.1136/jnnp.66.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 (Suppl 1):S3–10. doi: 10.1097/00002093-200000001-00002. [DOI] [PubMed] [Google Scholar]
  6. Katzman R. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol. 1976 Apr;33(4):217–218. doi: 10.1001/archneur.1976.00500040001001. [DOI] [PubMed] [Google Scholar]
  7. Kennedy D. O., Scholey Andrew B., Tildesley N. T. J., Perry E. K., Wesnes K. A. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002 Jul;72(4):953–964. doi: 10.1016/s0091-3057(02)00777-3. [DOI] [PubMed] [Google Scholar]
  8. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  9. Mohammadi M. R., Akhondzadeh S. Schizophrenia: etiology and pharmacotherapy. IDrugs. 2001 Oct;4(10):1167–1172. [PubMed] [Google Scholar]
  10. Mohs R. C., Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988;24(4):627–628. [PubMed] [Google Scholar]
  11. Perry E. K., Pickering A. T., Wang W. W., Houghton P. J., Perry N. S. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999 May;51(5):527–534. doi: 10.1211/0022357991772808. [DOI] [PubMed] [Google Scholar]
  12. Perry E. K., Pickering A. T., Wang W. W., Houghton P., Perry N. S. Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. J Altern Complement Med. 1998 Winter;4(4):419–428. doi: 10.1089/acm.1998.4.419. [DOI] [PubMed] [Google Scholar]
  13. Sky A. J., Grossberg G. T. The use of psychotropic medication in the management of problem behaviors in the patient with Alzheimer's disease. Med Clin North Am. 1994 Jul;78(4):811–822. doi: 10.1016/s0025-7125(16)30135-3. [DOI] [PubMed] [Google Scholar]
  14. Wake G., Court J., Pickering A., Lewis R., Wilkins R., Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol. 2000 Feb;69(2):105–114. doi: 10.1016/s0378-8741(99)00113-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES